



Tanvex submits TX05 BLA to FDA

Aug. 3, 2021

Tanvex BioPharma, Inc. (TWSE: 6541) proudly announced the submission of its Biologics License Application (BLA) for TX05 to US Food and Drug Administration (FDA). This is the second BLA for Tanvex filed with US FDA. TX05 is a proposed biosimilar to the reference product Herceptin® (trastuzumab).

Tanvex announced positive top-line efficacy and safety data from global Phase III clinical trial in Feb. 2021. According to data from IQVIA, Herceptin® US sales in 2020 was \$2.3 billion (USD).

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.